Clinical trial
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
NCT03759678 · IntraBio Inc, Industry · Active, not recruiting
Key facts
| NCT number | NCT03759678 |
|---|---|
| Title | N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) |
| Official title | Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study |
| Lead sponsor | IntraBio Inc, Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ataxia Telangiectasia, Louis Bar Syndrome |
| Intervention type | Drug |
| Interventions | IB1001 |
| Enrollment | 39 |
| Start date | Jan 8, 2020 |
| Primary completion | Mar 1, 2025 |
| Completion | Jul 1, 2025 |
| First posted | Nov 30, 2018 |
| Last update posted | Apr 30, 2025 |
| Countries | Germany, Spain, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: